ANP.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Jan 2024 @ 23:56):

Stats
Today's Volume	869 280
Average Volume	548 968
Market Cap	52.29M
EPS	$0 ( 2024-02-19 )
Next earnings date	( $0 ) 2024-07-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.90
ATR14	$0.00300 (5.36%)

Volume Correlation

Long: -0.22 (neutral)

Short: -0.74 (moderate negative)

Signal:(44.832) Neutral

Antisense Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Antisense Therapeutics Correlation - Currency/Commodity

-0.63
( weak negative )

-0.72
( moderate negative )

0.00
( neutral )

0.58
( weak )

Antisense Therapeutics Financials

Annual	2022
Revenue:	$1.58M
Gross Profit:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Revenue:	$1.58M
Gross Profit:	$1.55M (97.91 %)
EPS:	$-0.0179

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00920

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0209

Financial Reports:

No articles found.

Antisense Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Antisense Therapeutics

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.